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Background: Formula-fed (FF) infants often have harder stools and higher stool concentrations of fatty acid soaps
compared to breastfed infants. Feeding high sn-2 palmitate or the prebiotic oligofructose (OF) may soften stools,
reduce stool soaps, and decrease fecal calcium loss.
Methods: We investigated the effect of high sn-2 palmitate alone and in combination with OF on stool palmitate
soap, total soap and calcium concentrations, stool consistency, gastrointestinal (GI) tolerance, anthropometrics, and
hydration in FF infants. This double-blind trial randomized 165 healthy term infants 25–45 days old to receive Control
formula (n = 54), formula containing high sn-2 palmitate (sn-2; n = 56), or formula containing high sn-2 palmitate plus
3 g/L OF (sn-2+OF; n = 55). A non-randomized human milk (HM)-fed group was also included (n = 55). The primary
endpoint, stool composition, was determined after 28 days of feeding, and was assessed using ANOVA accompanied
by pairwise comparisons. Stool consistency, GI tolerance and hydration were assessed at baseline, day 14 (GI tolerance
only) and day 28.
Results: Infants fed sn-2 had lower stool palmitate soaps compared to Control (P =0.0028); while those fed sn-2+OF
had reduced stool palmitate soaps compared to both Control and sn-2 (both P <0.0001). Stool total soaps and calcium
were lower in the sn-2+OF group than either Control (P <0.0001) or sn-2 (P <0.0001). The HM-fed group had lower stool
palmitate soaps, total soaps and calcium (P <0.0001 for each comparison) than all FF groups. The stool consistency
score of the sn-2+OF group was lower than Control and sn-2 (P <0.0001), but higher than the HM-fed group (P <0.0001).
GI tolerance was similar and anthropometric z-scores were <0.2 SD from the WHO growth standards in all groups, while
urinary hydration markers were within normal range for all FF infants.
Conclusions: Increasing sn-2 palmitate in infant formula reduces stool palmitate soaps. A combination of high sn-2
palmitate and OF reduces stool palmitate soaps, total soaps and calcium, while promoting softer stools.
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Human milk (HM) is exceptionally complex containing
numerous components that function in a synergistic man-
ner. Nutritional components designed to improve infant
formula (IF) are often added and evaluated in a step-wise
process. However, IF ingredients may interact with each
other, and consequently, the evaluation of isolated ingredi-
ents is insufficient in assessing these complex relationships.
One example of such interactions involves the digestion of
triglycerides and the subsequent absorption of fatty acids
and calcium [1], processes which are dependent on both
lipid structure and intestinal environment (such as colonic
bacterial populations and pH).
Fatty acids in HM and IF triglycerides are esterified to
the sn-1, sn-2 and sn-3 positions of the glycerol back-
bone [2]. Palmitic acid (PA) comprises approximately 20
percent of total HM fatty acids [3], of which approxi-
mately two thirds is esterified to the triglyceride sn-2
position [2]. In contrast, greater than 80 percent of PA
in IF fat blends is esterified to the sn-1 and sn-3 posi-
tions [4]. During digestion, the sn-1 and sn-3 fatty acids
are hydrolyzed by pancreatic lipase. The selective activity
of pancreatic lipase on the sn-1 and sn-3 positions of the
triglyceride generates two free fatty acids and a corre-
sponding sn-2 monoglyceride. This sn-2 monoglyceride
is readily absorbed regardless of the structure of its
esterified fatty acid [1]. The absorption characteristics of
the free fatty acids are dependent on their structure. Of
the free fatty acids, saturated fatty acids are less readily
absorbed than unsaturated fatty acids and have the po-
tential to form insoluble fatty acid soaps, which can re-
sult in the loss of both calcium and energy in the feces.
Compared to the hydrolysis of HM triglycerides, hy-
drolysis of IF triglycerides generates more free PA with
the potential to bind calcium and form PA soaps [5].
Since any reduction in stool soap formation is likely to
result in reduced fecal loss of both energy and calcium,
the development of a structured triglyceride (closer to
HM with high sn-2 PA) and its addition to IF will be of
benefit to FF infants.
Other means of reducing fecal calcium loss are avail-
able and the activities of prebiotics are ideally suited to
this purpose. OF is a fructan oligosaccharide derived
from enzymatic hydrolysis of chicory root inulin and
consists of 2 – 8 fructose residues. It functions as a sol-
uble dietary fiber with prebiotic activities in that it is not
digested in the small intestine, but is fermented in the
colon, stimulating the growth of colonic populations of
beneficial bacteria [6] and lowering pH [7], which may
increase the solubility of calcium in the colon and
subsequently increase calcium absorption [8,9].
Stools are harder in FF infants than in infants fed
breast milk [5,10] and may be difficult to pass; therefore,
stool consistency is often a concern of parents of FFinfants [11]. Stool consistency is influenced by numerous
factors, including the presence of PA-calcium soaps [5]
and colonic fermentation of non-digestible oligosaccha-
rides [6]. Thus the addition of both high sn-2 PA triglycer-
ide and prebiotic to IF may improve stool consistency.
The objective of the present study was to evaluate the
effects of feeding IFs containing either high sn-2 palmi-
tate or high sn-2 palmitate with the addition of 3 g/L OF
compared to a Control formula. A HM-fed reference
group was also included. We determined the stool con-
centrations of fatty acid soaps and calcium as well as
stool consistency and frequency. Since runny or watery
stool may suggest altered water balance, urinary markers
of hydration were also measured.
Methods
Study population
In this multi-center, randomized, controlled, double-
blind, parallel-group study, healthy, term infants born at
37–42 weeks gestation were enrolled at 25–45 days of
age and randomized to receive one of three IFs. In
addition, a non-randomized reference group exclusively
receiving HM was included. FF infants had to be exclu-
sively consuming and tolerating a cow’s milk IF and the
parent/legal guardian must have previously made a deci-
sion to continue to exclusively formula feed. The pur-
pose of the study and the procedures, benefits and risks
involved in study participation were explained to the
parents/legal guardians of all participating infants before
written informed consent was obtained. Prior to imple-
menting any study procedures, each subject’s parent/
legal guardian voluntarily signed and dated the informed
consent.
Exclusion criteria included: a history of siblings with
documented cow’s milk protein intolerance/allergy; major
congenital malformations; suspected or documented sys-
temic or congenital infections (e.g., human immunodefi-
ciency virus, cytomegalovirus); infants who received any
medication (s) which were known or suspected to affect
fat digestion, absorption and/or metabolism (e.g., pancre-
atic enzymes), any vitamin and/or mineral supplements
containing calcium, suppositories, bismuth containing
medications, herbal supplements, or medications that
could neutralize or suppress gastric acid secretion; or con-
ditions requiring infant feedings other than those specified
in the protocol.
All infants were fed ad libitum for a period of four
weeks and were followed for a period of two weeks after
last study feeding. Parents and infants participated in
clinic visits at baseline, day 14 and day 28 with tele-
phone interviews at days 7, 21 and 42. At baseline, day
14 and day 28, anthropometric data were collected and
parents completed the Infant Gastrointestinal Symptom
Questionnaire (IGSQ) [12] to assess GI tolerance. For
Table 1 Selected nutrient composition, fatty acid profiles
and positional distribution of PA of the study formulas
Formula group
Nutrient/Ingredient Control sn-2 sn-2+OF
Energy, kcal/L 661 662 678
Protein, g/L 14 15 15
Total Fat, g/L 36 37 37
Carbohydrate, g/L 69 69 72
Calcium, mg/L 411 423 431
Oligofructose, g/L - - 3
Fatty acids, weight % of TFAs
C12:0, lauric 7.1 6.8 6.9
C14:0, myristic 4.1 3.4 3.5
C16:0, palmitic 21.1 22.5 22.5
C18:0, stearic 3.9 3.7 3.6
C18:1, oleic 39.4 40.1 40.0
C18:2, linoleic 18.5 17.2 17.1
18:3, linolenic 1.4 1.5 1.5
C20:4, arachidonic 0.3 0.4 0.4
C22:6, docosahexaenoic 0.2 0.2 0.2
Percent of PA (C16:0) in the sn-2 position 12.6 38.9 40.8
Control = bovine milk-based, whey-predominant, alpha-lactalbumin-enriched
term infant formula with 100% vegetable fat blend; PA = palmitic acid; sn-2 = high
sn-2 palmitate formula (Control formula modified to contain 60% vegetable fat
blend and 40% high sn-2 palmitate fat blend); sn-2+OF = high sn-2 palmitate
formula supplemented with oligofructose at 3.0 g/L; TFAs = total fatty acids.
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day 28 clinic visits, parents completed a stool consistency
and frequency diary. Prior to the day 28 clinic visit, par-
ents collected stool for analysis of fatty acid soaps and
mineral content. Adverse event information was collected
at all clinic visits and during all telephone calls.
The study was conducted between 13 September, 2010
and 20 December, 2011 at four hospitals in Taiwan: Mackay
Memorial Hospital, Taipei City; Mackay Memorial Hospital,
Hsinchu Branch; Chang Gung Medical Foundation, Taipei
Branch; and Chang Gung Medical Foundation, Linkuo
Branch. It was performed in accordance with the guidelines
of the Declaration of Helsinki in conformance with Inter-
national Conference on Harmonization, Good Clinical
Practice and the criteria described in 21 Code of Federal
Regulations 312.120 (Foreign Clinical Studies Not Con-
ducted Under an Investigational New Drug Application).
The study protocol, protocol amendments, and informed
consent form were reviewed and approved by each hospi-
tal’s Institutional Ethical Review Board according to ICH-
GCP guidelines.
Randomization
At study entry, FF infants were randomly assigned in a
2:2:2 ratio (block size of 6) utilizing the validated
randomization software, TriaLine system (INC Research),
to receive one of three study formulas. Site personnel were
provided with a subject randomization number and a
package number to assign to each subject. Assigned for-
mula packages were dispensed on study days 1 and 14.
Study formula was packaged identically except for the
unique 5 digit package identification number printed on
the label, so that the investigator, study staff, participants,
and care providers were blinded to the allocated treatment.
Composition of study formula
The three study formulas were of similar composition,
with the exception of the fat blend source and the pres-
ence of OF: 1.) Control formula, whey-predominant and
enriched in alpha-lactalbumin with a 100% vegetable fat
blend; 2.) sn-2 formula, Control formula with a fat blend
containing 60% Control vegetable oil and 40% high sn-2
palmitate vegetable oil; and 3.) sn-2+OF formula, the
sn-2 formula supplemented with 3.0 g/L OF (Orafti® P95,
BENEO-ORAFTI, Tienen, Belgium). Table 1 provides fatty
acid profiles, positional distribution of PA and selected
nutrient concentrations of each study formula.
Stool characteristics and biochemical composition
Information related to stool characteristics (stool con-
sistency and frequency) was collected using a three-day
stool diary that parents completed immediately prior to
the day 14 and day 28 visits. Each stool that was passed
during the three-day period was evaluated by theparent/caregiver according to a validated 5-point scale (1 =
Watery, 2 = Runny, 3 =Mushy Soft, 4 = Formed, 5 =Hard)
[5,10]. The number of bowel movements per day was also
recorded. An average stool consistency score and the aver-
age number of stools per day were determined for each
three-day period.
Stool samples were collected at home beginning on day
22 (±3 days). The collection involved use of diapers fitted
with a strip of Tegaderm tape (to facilitate stool retention
in the diaper) and placement of each freshly passed stool
in an amber plastic bag. The bag was weighed using a
portable gram scale and stored within a stool collection
container in a home freezer until ≈ 30 g had been col-
lected. Frozen stools were transported from home to study
center in an insulated bag, then transported on dry ice to
Covance Laboratories, Inc., Madison, Wisconsin, USA for
analysis. The analytical laboratory determined fatty acid
soap content utilizing a modified method of Quinlan et al.
[5]. Briefly, samples were thawed, wet weight determined,
then lyophilized and dry weight determined. Neutral lipids
were extracted from 0.5-1.0 g freeze-dried sample of stool
by reflux with petroleum ether. The remaining sample was
acidified utilizing acetic acid in order to convert fatty acid
soaps to free fatty acids, which were then isolated by reflux
with petroleum ether. Free fatty acids from each extract
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an anhydrous alkaline exchange resin. Fatty acid methyl
esters were synthesized by use of hydrochloric acid and
methanol followed by capillary gas chromatography ana-
lysis. Total fatty acid soaps were derived from the sum of
all measured individual fatty acid soaps. All fatty acid soap
data are reported as mg per g of dry weight stool. Percent
stool moisture was determined by measuring the stool
sample wet weight (g) and subtracting the dry stool weight
(g) after lyophilization, divided by the wet stool weight
and then multiplied by 100. Stool solids were determined
by subtracting % stool moisture from 100%. Stool calcium
content was determined by ICPL (Inductively Coupled
Plasma) Emission Spectrometry utilizing the AOAC Inter-
national Official Methods of Analysis protocol [13]. The
stool sample was dried, precharred, and ashed twice. It
was then treated with hydrochloric acid, dried, and added
to a 5% hydrochloric acid solution. The amount of calcium
in the solution was determined on the inductively coupled
plasma emission spectrometer by comparing emissions to
those of the standard solution.
Hydration assessment
Due to the possibility of looser, more watery stools in the
infants receiving sn-2 and sn-2+OF formulas, markers of
hydration, urine osmolality and urine specific gravity were
measured. Urine samples were collected at baseline and
day 28 clinic visits using a Medline pediatric urine collec-
tion bag. Urine was transferred from the urine collection
bag to two labeled Vacutainer® tubes for transport (one
without preservative for urine osmolality, and one with
preservative tablet for urine specific gravity). Samples were
shipped on day of collection at ambient temperature
to Covance Central Laboratory Services, Singapore.
Temperature was maintained during shipment using Gel-
Pak thermal insulators. Once samples were received at
Covance Singapore, they were frozen and shipped to Cov-
ance Central Laboratory Services, Indianapolis, Indiana,
USA for analysis of urine osmolality and urine specific
gravity using standard laboratory methods.
GI tolerance
The GI Symptom Burden Index Score [12] was used to
assess parent-reported GI tolerance. This index score is
based on a subset of 13 questions included in the IGSQ.
The IGSQ is a standardized, validated, interviewer-assisted
questionnaire containing 21 questions across 5 GI categor-
ies: stooling, vomiting, crying, fussiness, and flatulence,
allowing parents to report the frequency and intensity of
their infant’s GI symptoms from the previous 7 days. For
determination of the index score, the responses to 13 of the
questions are summed to produce a single score, which is a
measure of the total GI symptom burden. The potential
range for the GI Symptom Burden Index Score is 13 to 65;a score of 13 indicates low GI burden, while a score of 65
indicates high GI burden. Parent-reported GI tolerance was
descriptively summarized for each formula group and the
HM group at baseline, day 14, and day 28 clinic visits.
Adverse events
An adverse event (AE) was defined as any untoward, un-
desired, or unplanned event in the form of signs, symptoms,
disease, or laboratory or physiological observations that
occurred in an infant from the time of informed consent
signing until approximately 2 weeks after last assigned study
feeding. The event did not necessarily need to be causally
related to the study formula or study procedures. A serious
AE (SAE) was defined as an AE that resulted in death, was
life-threatening, required inpatient hospitalization or pro-
longation of an existing hospitalization, or resulted in a per-
sistent or significant disability or incapacity, resulted in
cancer, was a congenital anomaly or birth defect, or an im-
portant medical event. AEs were recorded by the hospital
staff during clinic visits and telephone contacts with parents
throughout the study and 14 days after completion of the
feeding portion of the study. Particular attention was paid
to GI AEs.
Anthropometry
Infants were weighed on an electronic infant scale (Seca
374, Hamburg, Germany) without a diaper; weight was
recorded to the nearest gram. A pediatric length board
(NWB LB 35-70-X; Ellard Instrumentation, Washington,
DC, USA) was used to measure recumbent length to the
nearest 0.1 cm; head circumference was measured with a
pediatric tape measure (Seca 212, Hamburg, Germany)
to the nearest 0.1 cm. All measures were taken twice
and the mean was calculated.
Statistical methods
Sample size was based on power calculations for the pri-
mary outcome (stool fatty acid soaps) and a key secondary
outcome (stool consistency). Based on these calculations,
23 infants per group were required for 90% power to de-
tect a mean (SD) between-group difference of 7% (7%) in
fatty acid soaps at α = 0.05; and 40 infants per group were
required for 90% power to detect a mean (SD) between-
group difference of 0.3 (0.4) points in the five-point stool
consistency scale at α = 0.05 (Details on these calculations
are provided in the Additional file 1). Based on the higher
number, a minimum of 40 infants per group was needed
for adequate power. To account for dropouts, enrollment
of 55 infants per group was required.
Comparison of the three FF groups was of primary
interest. There was no overall analysis for differences
among all four feeding groups, primarily because the
HM-fed group was included in the study as a reference
group. Therefore, it was considered appropriate to perform
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the HM-fed group. ANOVA was used to assess mean
differences in stool composition across the three FF
groups. Accompanying each overall analysis was a series
of pairwise comparisons conducted to test for differences
between each pair of FF groups using the pooled error
term. Additionally, a series of independent t-tests to com-
pare each of the FF groups separately with the HM-fed
group was conducted.
For analysis of stool consistency and stool frequency
data, a mixed model repeated measures ANCOVA was
used to compare the three FF groups. In addition, separ-
ate repeated measures analyses were done for pairwise
comparisons between the HM-fed group and each of the
three FF groups. All statistical tests were 2-sided and
performed at α = 0.05. A step-wise process was used to
control for multiple comparisons (Details on this process
are provided in Additional file 1).Figure 1 Study flow diagram. Control = bovine milk-based, whey-predom
vegetable fat blend; HM = human milk; sn-2 = high sn-2 palmitate formula
high sn-2 palmitate fat blend); sn-2+OF = high sn-2 palmitate formula suppResults
Study population
A total of 165 FF infants (randomized) and 65 HM-fed
infants (non-randomized) were enrolled and partici-
pated in the study (Figure 1) between September, 2010
and December, 2011. Infants in the randomized groups
were similar in terms of gestational age, age at enrollment,
birth order, gender and race (Table 2). Household charac-
teristics in terms of maternal age, parity, mode of delivery,
parents’ number of school years completed, marital status,
and infant feeding history, were similar for the three FF
groups.
Stool lipids and calcium
PA was the predominant fatty acid present in fecal fatty
acid soaps in all groups (Table 3). The concentration of
palmitate soaps in the sn-2 group (159.3 ± 42.0 mg/g dry
weight stool) was significantly lower than the Controlinant, alpha-lactalbumin-enriched term infant formula with 100%
(Control formula modified to contain 60% vegetable fat blend and 40%
lemented with oligofructose at 3.0 g/L.
Table 2 Baseline demographic characteristics of the study population
Feeding group
Control sn-2 sn-2+OF HM
(n =46) (n =51) (n =49) (n =49)
Infant characteristics
Age at enrollment, days1,2 34.5 (3.1) 35.2 (4.2) 35.2 (3.4) 34.8 (3.9)
Gestational age, weeks1,2 38.8 (1.2) 38.9 (1.2) 38.8 (1.1) 39.1 (1.0)
Gender, % male3,4 52 53 59 59
Birth order, % first born3,4 46 51 41 47
Parental characteristics
Maternal age, years1,2 30.7 (5.9) 31.4 (5.5) 31.6 (5.7) 30.5 (4.5)
Marital status, % married3,4 96 86 96 100
Mother’s number of school years completed1,2 13.7 (2.1) 14.1 (2.7) 13.8 (1.9) 14.6 (2.9)
Father’s number of school years completed1,2 13.8 (3.2) 14.1 (2.6) 13.3 (2.7) 15.1 (2.8)
1Mean (SD).
2No significant differences were observed based on overall and pairwise comparisons across the formula groups and independent 2 sample t-tests comparing the
FF groups to the HM group for infant age, gestational age, maternal age and years of school completed by the mother and father.
3Percentages are based on the number of subjects in each feeding group.
4No significant differences were observed based on overall and pairwise comparisons across the formula groups and HM based on overall and pairwise
comparisons using Fisher’s exact test for infant gender, infant birth order, and mother’s marital status.
Control = bovine milk-based, whey-predominant, alpha-lactalbumin-enriched term infant formula with 100% vegetable fat blend; HM = human milk; sn-2 = high
sn-2 palmitate formula (Control formula modified to contain 60% vegetable fat blend and 40% high sn-2 palmitate fat blend); sn-2+OF = high sn-2 palmitate
formula supplemented with oligofructose at 3.0 g/L.
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to the formula resulted in a further reduction (113.3 ±
43.1 mg/g; P <0.0001) (Figure 2). The stool palmitate
soaps of the HM-fed group were substantially lower than
any of the formula groups (26.0 ± 26.2 mg/g; P <0.0001).
Total fatty acid soap concentration in the sn-2 group
was similar to the Control group while the sn-2+OFTable 3 Stool fatty acid soaps (mg/g dry weight stool) at day
Primary fatty acid soap endpoints1
Control sn-2
(n =46) (n =5
C16:0 FA soap (palmitate) 186.9 ± 48.8 159.3 ± 4
Total FA soaps 272.8 ± 67.9 251.4 ±
Secondary endpoints - individual FA soaps1, 3
C12:0 FA soap (lauric) 4.6 ± 2.0 3.2 ± 1
C14:0 FA soap (myristic) 13.7 ± 4.5 9.6 ± 3
C18:0 FA soap (stearic) 37.8 ± 8.7 38.6 ±
C18:1 FA soap (oleic) 20.0 ± 8.7 29.3 ±
C18:2 FA soap (linoleic) 3.2 ± 1.6 3.4 ± 1
1Mean ± SD.
2Based on analysis of variance followed by pairwise comparisons for formula group
3Descriptively summarized; no statistical analysis done.
Control = bovine milk-based, whey-predominant, alpha-lactalbumin-enriched term i
sn-2 = high sn-2 palmitate formula (Control formula modified to contain 60% veget
palmitate formula supplemented with oligofructose at 3.0 g/L.
Statistical significance: a: P =0.0028 vs. control, b: P <0.0001 vs. control, c: P <0.0001group had lower total soap fatty acids than either of the
other two FF groups (P <0.0001, Table 3). The HM
group had lower total fatty acid soap concentrations
(63.5 ± 56.3 mg/g; P <0.0001) than any of the FF groups.
Other saturated fatty acid soaps such as lauric (C12:0),
myristic (C14:0), stearic (C18:0), oleic (C18:1) and lino-
leic (C18:2) were descriptively summarized (Table 3).28
Feeding group Statistically significant
group differences2
sn-2+OF HM
1) (n =49) (n =48)
2.0 a 113.3 ± 43.1b, c 26.0 ± 26.2d
aP =0.0028 vs. control
bP <0.0001 vs. control
65.1 175.6 ± 64.1b, c 63.5 ± 56.3d
cP <0.0001 vs. sn-2
dP <0.0001 vs. all formulas
.4 1.6 ± 1.4 0.3 ± 0.4
.0 6.0 ± 3.2 1.3 ± 1.5
9.8 31.4 ± 10.5 23.2 ± 20.5
9.9 15.5 ± 10.5 8.4 ± 8.8
.4 1.8 ± 1.7 1.6 ± 1.6
s, and independent t-tests for each of the formula groups vs. HM group.
nfant formula with 100% vegetable fat blend; FA = fatty acid; HM = human milk;
able fat blend and 40% high sn-2 palmitate fat blend); sn-2+OF = high sn-2
vs. sn-2 and d: P <0.0001 vs. all formulas.
Figure 2 Stool palmitate soaps (mg/g dry weight stool) at Day 28 according to feeding group. 1Values are means ± SD. The overall formula-fed
groups were analyzed by ANOVA followed by pairwise comparisons. The HM group was compared to each formula group using independent t-tests.
Means (± SD) significantly different from Control: *P =0.0028, †P <0.0001; significantly different from sn-2: ‡P <0.0001; significantly different from all
formula groups: §P <0.0001. Control = bovine milk-based, whey-predominant, alpha-lactalbumin-enriched term infant formula with 100% vegetable fat
blend; HM= human milk; dw= dry weight; sn-2 = high sn-2 palmitate formula (Control formula modified to contain 60% vegetable fat blend and 40%
high sn-2 palmitate fat blend); sn-2+OF = high sn-2 palmitate formula supplemented with oligofructose at 3.0 g/L.
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significantly lower (28.5 ± 7.3 mg/g, P <0.0001) than in
both the Control (38.0 ± 8.4 mg/g) and sn-2 groups
(39.4 ± 7.0 mg/g) but was not significantly different be-
tween the Control group and the sn-2 group (Figure 3).
Stool calcium in the HM-fed group was lower (17.6 ±Figure 3 Stool calcium (mg/g dry weight stool) at Day 28 according t
groups were analyzed by ANOVA followed by pairwise comparisons; the H
t-tests. Means (± SD) significantly different from Control: *P <0.0001; signific
formula groups: ‡P <0.0001. Control = bovine milk-based, whey-predominan
vegetable fat blend; dw = dry weight; HM = human milk; sn-2 = high sn-2 p
fat blend and 40% high sn-2 palmitate fat blend); sn-2+OF = high sn-2 palm8.4 mg/g; P <0.0001 for each comparison) than all FF
groups.
Stool consistency and frequency
The mean stool consistency is presented in Figure 4. Stool
consistency was similar for the Control and sn-2 groupso feeding group. 1Values are means ± SD. The overall formula-fed
M group was compared to each formula group using independent
antly different from sn-2: †P <0.0001; significantly different from all
t, alpha-lactalbumin-enriched term infant formula with 100%
almitate formula (Control formula modified to contain 60% vegetable
itate formula supplemented with oligofructose at 3.0 g/L.
Figure 4 Stool consistency scores at day 28 according to feeding group. 1Individual stool consistency scores were determined using a five
point scale for stool consistency (1 = watery, 2 = runny, 3 = mushy soft, 4 = formed, and 5 = hard). 2 Values are means (± SD). Means (± SD)
significantly different from Control: *P <0.0001; significantly different from sn-2: †P <0.0001; significantly different from all formula groups:
‡P <0.0001. Control = bovine milk-based, whey-predominant, alpha-lactalbumin-enriched term infant formula with 100% vegetable fat blend; HM= human
milk; sn-2 = high sn-2 palmitate formula (Control formula modified to contain 60% vegetable fat blend and 40% high sn-2 palmitate fat blend); sn-2+OF =
high sn-2 palmitate formula supplemented with oligofructose at 3.0 g/L.
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mean stool consistency that was mushy-soft. The stool
consistency score of the sn-2+OF group (2.7 ± 0.5) was be-
tween runny (category 2) and mushy-soft (category 3), and
was significantly lower than the other two FF groups
(P <0.0001). The HM-fed group had a significantly lower
stool consistency score than any of the FF groups (2.2 ±
0.5, P <0.0001), approaching the runny category. Hard
stools were absent in the Control, sn-2+OF and HM-fed
groups, and represented <0.4% of stools in the sn-2 group.
Percent of formed stools were 23%, 19%, 2% and 0; per-
cent mushy soft stools were 63%, 76%, 64%, and 23%; and
percent runny stools were 13%, 4%, 34%, and 70% in the
Control, sn-2, sn-2+OF, and HM-fed groups, respectively.
While no FF infants had watery stools, 7% of the HM-fed
infants did.
No differences in stool frequency were reported among
the FF groups but stool frequency was lower (P <0.0001)
in all FF groups compared with the HM-fed infants.
The average number of stools per day at day 14 was
1.4, 1.2, 1.3, and 3.6, while at day 28 was 1.0, 0.9, 0.9,
and 2.5, in the Control, sn-2, sn-2+OF, and HM-fed
groups, respectively.
GI tolerance
The GI Symptom Burden Index Scores were 18.9 ± 4.6,
19.2 ± 4.4, 18.7 ± 4.5, 18.5 ± 4.6 for Control, sn-2, sn-2+OF
and HM-fed groups, respectively. These results indicate
that the parent assessment of GI tolerance was similar
across all groups and that the GI burden of each of the
study feedings was low. Additionally, individual questionsfrom the IGSQ showed no evidence of an increase in
watery stools or increased gassiness with associated
discomfort.
Adverse events
The proportion of infants with physician-reported AEs
that emerged during the study were 42.6% for the Control
formula group, 46.4% for the sn-2 group, 35.8% for the sn-
2+OF group and 40.0% for the HM-fed group. AEs were
primarily distributed among GI disorders, skin/subcutane-
ous tissue disorders and infections. The percentages of
physician-reported GI AEs were: 18.5%, Control group;
19.6%, sn-2 group; 7.5%, sn-2+OF group; and 9.1%, HM-
fed group. Only three GI AEs were reported to be related
to the study feedings, and all occurred in the Control
group. One subject experienced hypomotility and another
subject experienced both hard stools and constipation and
discontinued from the study. No physician-reported, study-
related GI adverse events occurred in either of the two
experimental formula groups. The percentages of subjects
with at least one SAE were 7.4% in the Control group, 5.4%
in the sn-2 group, and 5.7% in the sn-2+OF group (the
HM-fed group had no SAEs), and the investigators catego-
rized these primarily as infections/infestations category.
None of the SAEs were considered study-related.
Hydration
All FF infants had urine osmolality and specific gravity
values within the normal range (osmolality: 50–645
mOsmol/kg for subjects 0 to 30 days of age, and 50–
1500 mOsmol/kg for subjects >30 days old at the time
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infants). Due to difficulties in obtaining samples for all
infants, the number of urine samples at day 28 for each
group ranged from 31 to 38. Physicians reported no inci-
dences of diarrhea in the Control, sn-2+OF or HM-fed
groups and one case of diarrhea in the sn-2 group,
which was not considered study-related.
Anthropometry
Z-scores for weight, length and head circumference were
near zero at baseline and days 14 and day 28. At day 28,
the results were as follows: mean weight-for-age Z-scores
were 0.015 ± 0.76, 0.110 ± 0.82, 0.073 ± 0.83, and −0.073 ±
0.74; length-for-age Z-scores were 0.015 ± 1.01, 0.027 ±
1.00, −0.029 ± 0.93, and 0.172 ± 0.82; and mean head
circumference-for-age-Z-scores were −0.197 ± 0.78, 0.126 ±
0.98, −0.200 ± 0.88, and −0.129 ± 0.62, in Control, sn-2,
sn-2+OF and HM-fed groups, respectively.
Discussion
The present study demonstrates stool palmitate soaps were
higher in infants fed a Control formula compared to the in-
fants who received a formula containing high sn-2 palmi-
tate structured lipid as part of the formula fat blend. These
results are consistent with previous studies evaluating stool
soaps [14,15] or PA absorption [16] in term infants. In both
the present study and in previous studies, the stool palmi-
tate soap and calcium concentrations of breast fed infants
are substantially lower than FF infants. This is most likely
due to two characteristics of HM: the high concentration of
sn-2 palmitate [2] and lower concentrations of calcium.
In previous studies evaluating higher sn-2 palmitate
products, the experimental formulas contained approxi-
mately 45-66% of PA in the sn-2 position. [14-16]. Carnielli
et al. compared a control formula to an ‘intermediate’ sn-2
palmitate formula (39% PA at sn-2) with a lipid blend simi-
lar to the sn-2 formulas used in the present study and a
higher sn-2 palmitate formula (66% PA at sn-2, similar to
HM) [16]. They found that feeding infants the intermedi-
ate sn-2 palmitate formula increased palmitate absorption
but did not impact total fat or calcium absorption com-
pared to the control formula group; whereas, feeding the
high sn-2 palmitate formula (66% PA at sn-2) significantly
increased absorption of all three parameters compared to
the other 2 formula groups. The sn-2 formulas used in the
present study consisted of a fat blend containing approxi-
mately 39% of PA at the sn-2 position. We found no re-
ductions in fecal excretion of total fatty acid soaps and
calcium in infants fed the formula containing sn-2 only.
These observations suggest that the formation of fatty acid
soaps is in part dependent on the concentration of the
sn-2 palmitate in the structured lipid provided.
The present study demonstrates that soap formation may
also be influenced by factors independent of triglyceridestructure, such as the presence of the prebiotic OF. This
prebiotic is a non-digestible oligosaccharide which is trans-
ported intact to the colon [17]. Here it is fermented by bac-
teria that are beneficial to the infant such as bifidobacteria
and lactobacilli to generate a series of short chain organic
fatty acids, such as acetate, propionate and butyrate as well
as lactate [9,18] and may impact intestinal pH [19]. Feeding
prebiotics to infants results in a reduction in fecal pH com-
pared with infants receiving control formula [20,21]; this
lower colonic pH may lead to increased solubilization of
minerals and increased calcium absorption [8]. Prebiotic fi-
bers also exert a trophic effect on epithelial cells throughout
the GI tract to improve mineral absorption, as demon-
strated in animals [22]. Several studies have demonstrated
an increase in calcium absorption and bone mineralization
following ingestion of prebiotic mixtures in pre-adolescents
and adolescents [9,23]. Stable isotope studies demonstrate
that this effect is due to increased colonic calcium uptake
[9]. In the present study, infants fed the sn-2+OF formula
had lower stool total fatty acid soaps and calcium concen-
trations than infants fed the Control or sn-2 formulas, sug-
gesting that a reduction in colonic pH may increase the
solubility of calcium in the colon, improving retention. A
metabolic balance study would confirm whether the re-
duced fecal calcium excretion observed in this study
corresponds to improved intestinal calcium retention and
absorption, and hence the availability of more calcium for
bone mineralization.
Stool consistency differs between breastfed and FF
infants, with breastfed infants having softer stools [5,10].
Quinlan et al. reported that fatty acid soaps and calcium
were the dominant factors related to stool hardness in
both FF and breastfed infants [5]. Besides the presence
of fatty acid soaps and calcium, other factors may impact
stool consistency including consumption of prebiotics
such as oligosaccharides, which occur naturally in breast
milk [24]. Consumption of oligosaccharides has been
shown to soften stools in infants [25,26]. The mechan-
ism for OF-mediated stool softening differs from that of
high sn-2 palmitate structured lipids, although the exact
mechanism is unclear. It is known that OF serves as a
substrate for select colonic bacteria to increase microbial
mass, increase stool bulk [27] and improve stool con-
sistency [26,28]. In the present study, infants fed sn-2
+OF formula had significantly softer stools, and lower
total soaps, palmitate soaps and calcium than infants fed
either sn-2 or Control formula. Although there was a
difference in the palmitate soaps between the Control
and sn-2 groups, stool softness, total fatty acid soap, and
stool calcium concentrations did not differ between
them, suggesting that other factors besides a reduction
in palmitate soaps contributes to stool softness.
GI tolerance determined using the IGSQ survey and
physician reported GI adverse events were similar in all
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of softer, looser or watery stools in formulas supplemented
with prebiotics compared to control formulas [6,18,29].
A formula containing both a structured lipid (high sn-2
PA) and a mixture of galacto-oligosaccharide and fructo-
oligosaccharide (8 g/L) resulted in a higher proportion of
watery and runny stools than a control formula [29]. The
EU raised concerns about water balance and the potential
for dehydration of infants receiving such formulas [30].
However, Closa-Monasterolo et al. reported normal water
balance when infants received a formula containing 8 g/L
of an inulin/OF mix [31]. The current study did not find
an increase in the number of watery stools in the sn-2+OF
group compared to the other 2 formula groups. In addition,
no cases of diarrhea were reported in the sn-2+OF group
and only one case in the sn-2 group. These results demon-
strate that the formulas evaluated in this study do not
negatively impact water balance of term infants.Conclusions
This study demonstrates the interaction of multiple diet-
ary components to provide beneficial outcomes on stool
composition and consistency in term infants. Feeding IF
containing sn-2 palmitate and OF results in reduced
palmitate soaps, total fatty acid soaps, and calcium in
stool and is well tolerated. This combination of ingredi-
ents also promotes the formation of softer stools which
are of intermediate consistency between those of HM-
fed infants and those of infants fed standard or sn-2 only
enriched formulas.Additional file
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